Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin By Ogkologos - February 23, 2026 79 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-905/EV-303 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Sunitinib December 18, 2020 31-Year-Old Woman Diagnosed with Breast Cancer Just 11 Days Before Her... June 21, 2021 Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC June 1, 2022 For HPV-Positive Women, Test Can Guide Cervical Cancer Screening Follow-Up October 11, 2018 Load more HOT NEWS As Use of Genomic Data Expands in Cancer Care, Patients Share... How Can I Get the Latest Cancer Drug? How My Advanced Colorectal Cancer Diagnosis Led Me to Patient Advocacy Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait
